July 2004

Contents

Editorial

Volume 5 Number 6 July 2004

Treatment alerts

A round-up of news about access to treatments, with links to sources

Conference reports

XIII International HIV Resistance Workshop 8-12 June 2004, Tenerife

Risk of NNRTI-resistance during STI: implications for SMART and other STI studies

Persistent nevirapine resistance following mother to child transmission interventions

Tipranavir resistance and viral response: L90M did not reduce response, recommendation to use with T-20

Resistance in the UK: new approach to epidemiological studies

Low AZT activity against HIV-2 infection

No evidence for cross resistance between nevirapine and d4T

Experimental compounds to target viral expression in latent cells

Case of MDR reinfection with MDR virus

Keystone HIV Pathogenesis and Vaccine Development Report 12-18 April 2004, Whistler, British Columbia, Canada

Keystone HIV Pathogenesis and Vaccine Report

Antiretrovirals

CD4 entry criteria dropped for UK tipranavir named patient access

Tenofovir/FTC co-formulation expected in US by September

Guidelines for T-20

Persistent HIV viraemia fosters immunologic harm and viral evolution

Latent drug-resistant HIV harboured for years

Women's health

Smoking during HIV infection may alter the natural history of HPV infection and increase the risk of cervical disease

Paediatric care

Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with HIV

PK and drug interactions

Non-prescription simvastatin in the UK: contraindicated with many HIV medications

Label changes for indinavir warn of several interactions including atazanavir and PDE5 inhibitors

HIV prevention and transmission

Sexual transmission of HIV by acutely infected individuals has a disproportionate effect on the spread of HIV and may explain the current pandemic

On the web

Online medical resources

Conference abstracts

Treatment Access

Journal articles

Online publications

PDFs

Volume 5 Number 6 July 2004 PDF